Oncolytics Biotech Inc.

499 articles with Oncolytics Biotech Inc.

• Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

  4/2/2020

  93.3% clinical benefit rate 86% improvement over historical overall survival rates at recommended phase 2 dose Pelareorep stimulates robust antitumor adaptive immune response   [02-April-2020]   SAN DIEGO and CALGARY, Alberta , April 2, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intr

• Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

  3/24/2020

  Oncolytics Biotech® Inc. announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1.

• Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

  3/5/2020

  Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced its financial results and operational highlights for the quarter and year ended December 31, 2019.

• Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

  2/28/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Thursday, March 5, 2020 following release of its fourth quarter and year end 2019 financial results.

• Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

  1/27/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer.

• Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

  1/22/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today stated that the previously announced abstract for a poster to be presented at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO in San Francisco, has been published

• Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

  1/13/2020

  Safety cohort in the investigator sponsored multiple myeloma study, receiving both carfilzomib and Opdivo®, is now complete and pelareorep will be added to the combination in the next cohort in the coming weeks

• Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

  1/9/2020

  Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that ROTH Capital Partners will conduct a Key Opinion Leader call for their institutional clients.

• Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

  12/12/2018

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo®(nivolumab) to treat relapsed multiple myeloma patients.

• Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress

  10/11/2018

  Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data

• Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies

  10/2/2018

  Oncolytics Biotech® Inc. today announced publication of important research in the peer-reviewed journal Cancer Immunology Research.

• Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

  9/12/2018

  Oncolytics Biotech® Inc. today announced a clinical collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer.

• 

  Top 6 Biotech Stocks of 2017

  12/20/2017

  When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.

• Acerus Appoints Mr. Mark Lievonen to Its Board of Directors

  12/7/2017

  The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.

• Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer

  12/5/2017

  The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients in a pivotal phase 3 registration study.

• Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer

  11/30/2017

  The SAB will provide Oncolytics with significant clinical expertise and experience in breast cancer drug development in both the U.S. and Europe.

• 

  Oncolytics Biotech, Adlai Nortye Forge $86.6M Reolysin Deal

  11/17/2017

  Under the terms of The Agreement, Adlai will have exclusive development and commercialization rights to REOLYSIN in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.

• Oncolytics Biotech Announces 2017 Third Quarter Results

  11/8/2017

  Oncolytics Biotech today announced its financial results and operational highlights for the quarter ended September 30, 2017.

• Oncolytics Biotech Appoints Deborah Brown to Board of Directors

  11/2/2017

  "Ms. Brown's wealth of experience in new product launches and market expansion will lend valuable insights as we progress REOLYSIN toward commercialization," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

• Oncolytics Biotech Announces Successful End-Of-Phase II Meeting With FDA For REOLYSIN In Metastatic Breast Cancer

  9/18/2017